Views & Analysis | Perspectives on pharma industry issues

R&D

Agentic AI and the human element: Building trustworthy autom...

The future of clinical trials isn’t about replacing people. It’s about empowering them with smarter tools.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

R&D

Hexagonal rendering of AI concept on dark blue background

Results, reality, and recalibration: Unpacking AI hype at SC...

SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.

Digital

AI scientists and the robotic labs of tomorrow

AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.

Oncology

Daiichi Sankyo gears up for five ADC launches in 2026

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.

Sales & Marketing

Why a healthy search strategy can power pharma brand growth

‘Cyber-chondria’ has become an endemic part of our daily lives since the term - which describes people who search online to understand symptoms and improve their health - was coined in

R&D

How small molecule-focused CDMOs can navigate the impact of ...

As large-molecule drugs and weight-loss therapeutics dominate headlines, the pharmaceutical industry faces legislative pressures, funding cuts, and cascading supply chain disruptions.

R&D

Sponsored

Innovative sublingual medication for improved stroke care

Stroke poses a major threat to public health, and this threat is predicted to worsen in the years to come.

Sales & Marketing

virtual electronic medical record interface

Sponsored

5 forces reshaping pharma commercialisation in 2026

As infrastructure bottlenecks ease and regulatory frameworks mature, pharma's AI adoption is shifting from proof-of-concept to production-grade deployment

Sales & Marketing

Swiss train speeding across bridge against landscape background

A fast start to 2026 signals continued investor confidence i...

Key factors in Switzerland’s success that could make other European life sciences hubs more attractive to investors.

Digital

AI scientists and the robotic labs of tomorrow

AI scientists will no longer operate at the margins of life sciences research - they'll become essential collaborators in the labs of tomorrow.

Digital

On digital health and the Rural Health Transformation Progra...

As reported in January this year, the United States Centers for Medicare & Medicaid Services (CMS) rolled out $10 billion in

Market Access

Biotech leaders: ‘They're shoving this industry into the arm...

At the Biotech Showcase during JPM Week, biotech leaders expressed frustration at the US's lack of concern about Chinese biotech progress.

Market Access

European biopharma at a crossroads

If Europe can bridge its operational gaps while leveraging its scientific base, it can carve out a distinctive and sustainable leadership position.

Oncology

Sponsored

Collaboration & personalisation in rare disease R&D, with AO...

For Rare Disease Day, in an AOP Health-sponsored podcast Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, discussed their work.

Oncology